Implantica AG Q2 2025 Presentation Details
Implantica AG (publ) is excited to announce an upcoming presentation focusing on the financial results from the second quarter of 2025. This important event is scheduled for 15:00 CEST on a forthcoming date in August. Concurrently, an interim report for this period will be released early in the morning, providing investors with vital insights and updates.
How to Attend the Presentation
The presentation will be delivered in English through an audiocast accompanied by a teleconference. Interested attendees can participate by accessing the webcast link that will be shared prior to the event, ensuring everyone has the opportunity to be involved.
Participate via Webcast
For those planning to join the presentation through the audio webcast, the details will be available shortly. This format allows investors to follow the presentation conveniently from anywhere.
Join via Teleconference
If you prefer to engage through teleconference, please make sure to register ahead of time. Following registration, participants will receive a phone number and a conference ID, facilitating smooth access to the session.
Featured Speakers
The event will feature key insights from several knowledgeable individuals within Implantica:
- CEO Peter Forsell
- CFO Andreas Öhrnberg
- Chief Corporate Affairs Officer Nicole Pehrsson
Contact Information
For additional details concerning the presentation, please reach out to Nicole Pehrsson in the Investor Relations department. She can be contacted directly via phone, and she is available to answer any specific questions you may have.
Implantica is proudly listed on the Nasdaq First North Premier Growth Market in Stockholm, highlighting the company's commitment to growth and innovation in the health technology sector.
About Implantica
Implantica is a pioneering medtech group actively working to integrate advanced technologies into healthcare solutions. One of their leading innovations, RefluxStop™, has been developed as a CE-marked implant designed to prevent gastroesophageal reflux. This product represents a potential breakthrough in the treatment of reflux conditions, backed by encouraging outcomes from clinical trials.
In addition to this key product, Implantica is committed to enhancing eHealth initiatives inside the body, through robust technology systems that monitor health conditions remotely. Their product pipeline is marked by two main platforms: an eHealth technology that tracks health markers and a wireless energy system capable of powering implants without the need for invasive procedures.
Frequently Asked Questions
What is the date and time of Implantica's presentation?
Implantica's presentation is set for 15:00 CEST on a date in August.
How can I participate in the presentation?
You can join the presentation via a webcast or teleconference. Registration details will be available prior to the event.
Who will be speaking during the event?
The speakers for the event include CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson.
What is Implantica known for?
Implantica is focused on innovative medtech solutions, particularly their leading product, RefluxStop™, which addresses gastroesophageal reflux.
Where is Implantica listed?
Implantica is listed on the Nasdaq First North Premier Growth Market, emphasizing their growth ambitions in the medtech industry.
